MED — Medifast Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesBalancedSmall CapContrarian

Annual income statement for Medifast, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	714	935	1,526	1,599	1,072
Cost of Revenue
Gross Profit	537	698	1,128	1,140	776
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	623	801	1,310	1,414	946
Operating Profit	91	134	216	185	126
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	92.4	134	216	184	129
Provision for Income Taxes
Net Income After Taxes	77.9	103	164	144	99.4
Net Income Before Extraordinary Items
Net Income	77.9	103	164	144	99.4
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	77.9	103	164	144	99.4
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	6.43	9.14	13.9	12.7	9.1
Dividends per Share